DEF 14A: bioAffinity Technologies Seeks Stockholder Approval for Key Proposals at Upcoming Annual Meeting

bioAffinity Technologies is holding its annual stockholder meeting on June 4, 2024, to vote on key proposals including director elections, an incentive compensation plan, and an increase in authorized shares.

Summary

• bioAffinity Technologies is holding its Annual Meeting of Stockholders on June 4, 2024, in San Antonio, Texas.
• Stockholders will vote on several proposals, including the election of eight directors, approval of the 2024 Incentive Compensation Plan, and an amendment to increase authorized common stock from 25,000,000 to 100,000,000 shares.
• They will also vote to ratify the appointment of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
• Additionally, stockholders will consider approving the issuance of up to 1,632,000 shares upon exercise of warrants issued in a private placement that closed on March 8, 2024.
• A proposal to adjourn the meeting, if necessary, to solicit additional votes for the Increase In Authorized Shares Proposal and the Warrant Exercise Proposal will also be voted on.
• The Board of Directors recommends voting FOR all proposals.

Sentiment

Score: 7

Explanation: The document is primarily informational, outlining proposals for a stockholder vote. The tone is professional and forward-looking, with emphasis on growth and strategic flexibility. The potential dilution from warrant exercises is a minor concern, but overall the sentiment is moderately positive.

Positives

• The Board is committed to sound corporate governance practices.
• The Board has implemented a majority vote standard for director elections.
• The company has adopted a Code of Ethics and Business Conduct applicable to all directors, officers, and employees.
• The company maintains a policy on insider trading.
• The company is focused on attracting and retaining highly skilled professionals.

Negatives

• Approval of the Warrant Exercise Proposal will cause dilution to existing stockholders.
• Failure to approve the Warrant Exercise Proposal could adversely impact the company's ability to fund operations.
• An increase in authorized shares may make it more difficult to obtain control of the company.

Risks

• Failure to obtain stockholder approval for the Warrant Exercise Proposal could result in the loss of potential funding.
• Future issuances of common stock could dilute existing stockholders' ownership.
• The company's compensation policies and programs could potentially encourage excessive risk-taking.

Future Outlook

The company anticipates seeking future equity financing opportunities and will evaluate opportunities that are presented to us.

Management Comments

• As President and Chief Executive Officer of bioAffinity Technologies, I am greatly encouraged by the growing adoption and use by physicians of our first test, CyPath Lung, a noninvasive test for lung cancer, and of the technological advancements that our team continues to make in its fight to address the urgent need for noninvasive, early-stage diagnosis.
• Your trust in our team and belief in our technology are invaluable.

Industry Context

bioAffinity Technologies operates in the diagnostics and therapeutics industry, focusing on lung cancer and other lung diseases. The proposals outlined in the proxy statement reflect the company's efforts to secure funding, incentivize employees, and maintain compliance with regulatory requirements, all of which are common activities for companies in this sector.

Comparison to Industry Standards

• The company's executive compensation practices, including the use of stock options and restricted stock awards, are consistent with industry standards for emerging growth companies in the biotechnology and diagnostics sectors.
• The proposed increase in authorized shares is a common strategy for companies seeking to maintain flexibility for future financing and strategic transactions.
• The company's engagement of WithumSmith+Brown, PC as its independent registered public accounting firm aligns with industry practices for ensuring financial transparency and compliance.

Related Party Transactions

• Maria Zannes and Steven Girgenti purchased Bridge Notes in August 2022.
• PPLS acquired the laboratory assets of Village Oaks Pathology Services, P.A. on September 18, 2023.
• Mr. Girgenti, the Cranye Girgenti Testamentary Trust, Gary Rubin, The Harvey Sandler Revocable Trust, a trust of which Mr. Rubin is a co-trustee, Ms. Zannes and Dr. Joyce consented to an amendment of the terms of the outstanding warrants that they own.

Stakeholder Impact

• Approval of the proposals will impact shareholders through potential dilution and increased company flexibility.
• Employees may benefit from the 2024 Incentive Compensation Plan.
• The company's ability to fund operations and advance clinical trials could be affected by the outcome of the warrant exercise proposal.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will hold its Annual Meeting of Stockholders on June 4, 2024.
• The company will file a Registration Statement on Form S-8 relating to the shares reserved for issuance under the 2024 Plan.

Key Dates

Keywords

stockholders, proxy, directors, shares, warrants, compensation, bioAffinity, meeting, approval